a proof of principle study of ondansetron for the prevention of vasovagal syncope: the eleventh prevention of syncope trial (post11)

Conditions: Vasovagal Syncope (VVS); Syncope

Summary: about 20% of adults faint recurrently. these patients are often highly symptomatic, have problems with employment and driving, can be injured, and have poor quality of life. there are few therapies that have withstood the test of randomized clinical trials. the investigators will conduct a prospective, randomized, parallel, double-blind, proof-of-concept study that tests the hypothesis that serotonin 5ht3 receptor inhibition with ondansetron prevents tilt-induced vasovagal syncope (vvs) and pre-syncope in patients with clinical vvs. a total of 70 patients with quantitative clinical diagnostic criteria for vvs and at least 1 syncopal spell in the preceding year will be randomized in a double-blind acute phase 2 study to ondansetron 8 mg po bid x 2 doses or matching placebo. the endpoint will be presyncope or syncope associated with diagnostic hemodynamic changes. these data should provide useful preliminary data as a foundation on which to conduct a subsequent randomized clinical trial.

this will be a randomized, double-blind, parallel-arm study in which the subjects will undergo a tilt table test following 2 doses of ondansetron 8 mg po (evening before and morning of study) or after 2 doses of matching placebo (on separate days). on the morning of the study, the fasting subject (except for medications) will be instrumented, on an empty bladder. ecg electrodes will be applied to monitor continuous heart rhythm. bp will be monitored continuously using a finger volume clamp method using one or more of several extant devices, and calibrated with intermittent brachial cuff measurements. one intravenous cannula will be placed in the contralateral arm (to the bp cuff) for blood sampling. 3.9. tilt table protocol: following the insertion of the venous cannulae, a period of at least 20 minutes will be allowed to elapse before a 10-minute basal control (baseline) period. baseline data will be digitally recorded in this time. in the last 5 minutes of this period, blood will be drawn for fractionated plasma catecholamines. the table will be rapidly raised to 80 degrees for up to 60 minutes. the investigators are avoiding tilt test methods with provocative medications to avoid the issue of multiple causal factors. at 10 minutes and 30 minutes following onset of tilt (or at the onset of severe presyncope or hypotension \[systolic bp \<70 mmhg\]), venous fractionated catecholamines will be sampled. the study will be terminated if the subject develops syncope or at the completion of the protocol. 3.10. assessment of central volume changes with upright posture: segmental bioelectrical impedance (bei) will measure fluid shifts through the study to determine central volume changes with upright posture and in response to changing levels of co2. the fluid content in the upper torso (chest), the lower torso (abdominal), thigh, and calf will be assessed. bei is measured by passing a small current between electrodes and measuring the impedance with voltage-sensing electrodes to determine fluid content in four regions of the body . body segment volume is inversely proportional to electrical resistance (v\~1/r), so an increase in resistance reflects a loss of body fluid. 3.11. questionnaires: a brief online questionnaire will be administered to the patients to get a metric of their health-related quality of life (rand-36), and anxiety and depression symptoms (hads). this will be administered through redcap survey.

Eligibility criteria:
inclusion criteria: (a) ≥1 syncopal spells in the year preceding enrolment (b) ≥-2 points on the calgary syncope symptom score( accurate calculation for diagnosis of vasovagal syncope) (c) age ≥18 years with informed consent exclusion criteria: 1. other causes of syncope, such as ventricular tachycardia, complete heart block, orthostatic hypotension or hypersensitive carotid sinus syndrome 2. an inability to give informed consent 3. important valvular, coronary, myocardial or conduction abnormality or significant arrhythmia 4. hypertrophic cardiomyopathy 5. a permanent pacemaker 6. a seizure disorder 7. hypertension defined as \>160/90 mm hg 8. pregnancy 9. lactating women 10. glaucoma 11. medications with known effects on bp 12. known hypersensitivity to ondansetron and related medications 13. other factors which, in the investigator's opinion, would prevent the subject from completing the protocol.

Keywords: ondansetron